# VC Fonds Technologie Berlin

> VC Fonds Technologie Berlin is a VC fund in Berlin backing Software and Health Care. See 13 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Berlin, Germany
- Total investments: 13
- Last investment: Aug 2019
- Lead investor: 0%
- Last updated: Aug 2026

VC Fonds Technologie Berlin is a VC fund in Berlin focused on Software and Health Care. VC Fonds Technologie Berlin GmbH is a joint initiative of Investitionsbank Berlin (IBB) and the State of Berlin.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 3 | 23% |
| Health Care | 3 | 23% |
| Automotive | 2 | 15% |
| Therapeutics | 2 | 15% |
| Biotechnology | 2 | 15% |

27 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 23% |
| Series A | 3 | 23% |
| Series C | 2 | 15% |
| Series D | 2 | 15% |
| Funding Round | 2 | 15% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 9 | 69% |
| United States | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mika | Mika is a digital platform that empowers cancer patients. It aims to help improve cancer patients' mental health and well-being. Mika was created in collaboration with leading research institutions. The company was established in 2017 and is headquartered in Berlin, Germany. |  | Seed | Aug 06, 2019 |  |
| German Autolabs | German Autolabs empowers mobile workers in logistics with voice assistance, increasing efficiency and improving quality of service in many transport industries. Their unique modular technology can be deployed in driver apps, scanners and vehicles. German Autolabs builds industry-specific solutions that augment daily workflows of professionaldrivers, couriers and delivery staff. Their assistant skills speak the language of logistics and are used by leading providers around the world. | $7.7M | Seed | Feb 18, 2019 |  |
| OMEICOS Therapeutics | OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. | $18.6M | Series C | Nov 02, 2018 |  |
| Contentflow | Contentflow is the global Next-Gen SaaS solution for multichannel, independent live streaming for events, conferences and media coverage. Contentflow develops software for video-livestreaming your event in flawless quality to any mobile and stationary device available. | $2.2M | Seed | Oct 29, 2018 |  |
| Thermondo | Thermondo promote the energy transition with innovative heat solutions.Directly to the customer, providing superior energy products. Thermondo is a an integrated energy company offering state-of-the-art energy efficiency services. Thermondo became the largest installer of heating solution in Germany applying digital process excellence and qualitymanagement. They believe in deep vertical integration in order to achieve market disrupting quality and an outstanding customer experience. | $23M | Series D | Nov 03, 2017 |  |
| OMEICOS Therapeutics | OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. | $9.1M | Series B | Mar 01, 2017 |  |
| Eternygen | Eternygen is a Berlin based start up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen’s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseaseswith dramatically increasing prevalences in the last decades. Eternygen’s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes and obesity.Company’s emphasis is the development of a safe and effective drug for treatment of these widespread diseases via targeted adjustment of underlying metabolic failure. | $8.8M | Series A | Jan 09, 2017 |  |
| Meetrics | Since 2008 Meetrics provides cutting edge solutions to master online marketing across all channels, creating a transparent and a more efficient digital eco-system. The key areas Meetrics focuses on are: Viewability, Fraud Prevention, Brand Safety and Audience Verification. As the first European vendor Meetrics is being accredited by the mostrelevant industry committee, the MRC, for both measuring Display and Video Ads. |  |  | Sep 13, 2016 |  |
| Babble | Babble is a magazine and online community site that offers information and lifestyle content for urban hipsters. It covers beauty, home, food, travel, entertainment, parenting, and more. Babble was founded by Alisa Volkman and Rufus Griscom in December 2006 and is based in New York, USA. | $22M | Series C | Jul 08, 2015 |  |
| OMEICOS Therapeutics | OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. | $6.8M | Series A | Apr 15, 2015 |  |

10 of 13 investments shown.

## Co-investors
- [KfW](https://shizune.co/investors/profile/kfw) — VC Fund, 4 deals together
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 3 deals together
- [SMS Group](https://shizune.co/investors/profile/smsgroup) — VC Fund, 3 deals together
- [Vesalius Biocapital Partners](https://shizune.co/investors/profile/vesalius-biocapital-partners) — VC Fund, 3 deals together
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund, 2 deals together
- [The Falck Revocable Trust](https://shizune.co/investors/profile/the-falck-revocable-trust) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Health Care Investors in Germany](https://shizune.co/investors/health-care-investors-germany)
- [Health Care VC Funds in Germany](https://shizune.co/investors/health-care-vc-funds-germany)
- [Biotech VC Funds in Germany](https://shizune.co/investors/biotech-vc-funds-germany)
- [Biotech Investors in Germany](https://shizune.co/investors/biotech-investors-germany)
- [Biotechnology VC Funds in Germany](https://shizune.co/investors/biotechnology-vc-funds-germany)
- [Medical Device Investors in Germany](https://shizune.co/investors/medical-device-investors-germany)

## FAQ

### What does VC Fonds Technologie Berlin invest in?

VC Fonds Technologie Berlin invests primarily in Software, Health Care and Automotive startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did VC Fonds Technologie Berlin last invest?

The most recent investment recorded for VC Fonds Technologie Berlin closed in Aug 2019. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co